Literature DB >> 17498064

Src family kinases and lipid mediators in control of allergic inflammation.

Juan Rivera1, Ana Olivera.   

Abstract

The Src family kinases Fyn and Lyn are important modulators of the molecular events initiated by engagement of the high-affinity IgE receptor (Fc epsilon RI). These kinases control many of the early signaling events and initiate the production of several lipid metabolites that have an important role in regulating mast cell responses. The intracellular level of phosphatidylinositol (3,4,5)-trisphosphate (PIP(3)), which is produced by phosphatidylinositol 3-OH kinase, plays an important role in determining the extent of a mast cells response to a stimulus. Enhanced levels lead to a hyperdegranulating phenotype (as seen in SHIP-1(-/-) and Lyn(-/-) mast cells), whereas decreased levels cause hypodegranulation (as seen in Fyn(-/-) mast cells). Downregulation of mast cell phosphatase and tensin homologue deleted on chromosone 10 expression, a phosphatase that reduces cellular levels of PIP(3), caused constitutive cytokine production, demonstrating that this response is particularly sensitive to PIP(3) levels. Lyn and Fyn are also intimately linked to other lipid kinases, like sphingosine kinases (SphK). By producing sphingosine-1-phosphate (S1P), SphKs contribute to mast cell chemotaxis and degranulation. In vivo studies now reveal that circulating S1P as well as that found within the mast cell is important in determining mast cell responsiveness. These studies demonstrate the connection between Src protein tyrosine kinases and lipid second messengers that control mast cell function and allergic responses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498064     DOI: 10.1111/j.1600-065X.2007.00505.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  35 in total

1.  Inhibition of mast cell degranulation by a chimeric toxin containing a novel phosphatidylinositol-3,4,5-triphosphate phosphatase.

Authors:  Bruce J Shenker; Kathleen Boesze-Battaglia; Ali Zekavat; Lisa Walker; Dave Besack; Hydar Ali
Journal:  Mol Immunol       Date:  2010-09-21       Impact factor: 4.407

2.  CD84 negatively regulates IgE high-affinity receptor signaling in human mast cells.

Authors:  Damiana Álvarez-Errico; Irene Oliver-Vila; Erola Ainsua-Enrich; Alasdair M Gilfillan; César Picado; Joan Sayós; Margarita Martín
Journal:  J Immunol       Date:  2011-11-07       Impact factor: 5.422

3.  Fyn kinase regulates type II PtdIns 4-kinases in RBL 2H3 cells.

Authors:  Naveen Bojjireddy; Ranjeet Kumar Sinha; Gosukonda Subrahmanyam
Journal:  Mol Cell Biochem       Date:  2013-10-31       Impact factor: 3.396

Review 4.  Understanding the mechanisms of anaphylaxis.

Authors:  Richard D Peavy; Dean D Metcalfe
Journal:  Curr Opin Allergy Clin Immunol       Date:  2008-08

Review 5.  Anchoring junctions as drug targets: role in contraceptive development.

Authors:  Dolores D Mruk; Bruno Silvestrini; C Yan Cheng
Journal:  Pharmacol Rev       Date:  2008-05-15       Impact factor: 25.468

Review 6.  A current understanding of Fc epsilon RI-dependent mast cell activation.

Authors:  Juan Rivera; Ana Olivera
Journal:  Curr Allergy Asthma Rep       Date:  2008-03       Impact factor: 4.806

Review 7.  The tyrosine kinase network regulating mast cell activation.

Authors:  Alasdair M Gilfillan; Juan Rivera
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

Review 8.  Adapters in the organization of mast cell signaling.

Authors:  Damiana Alvarez-Errico; Eva Lessmann; Juan Rivera
Journal:  Immunol Rev       Date:  2009-11       Impact factor: 12.988

9.  The role of oxidative stress in the pathogenesis of asthma.

Authors:  You Sook Cho; Hee-Bom Moon
Journal:  Allergy Asthma Immunol Res       Date:  2010-04-29       Impact factor: 5.764

10.  Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.

Authors:  Jiyuan Ke; R Lakshman Chelvarajan; Vishal Sindhava; Darrell A Robertson; Lazaros Lekakis; C Darrell Jennings; Subbarao Bondada
Journal:  Mol Cancer       Date:  2009-12-31       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.